Navigation Links
OncoGenex Reports Financial Results for Fourth Quarter and Fiscal Year 2008 and Provides Outlook for 2009
Date:3/11/2009

nts that could be deemed forward-looking statements.

The potential risks and uncertainties associated with forward-looking statements include, among others, the possibility that an agreement with the FDA cannot be reached regarding a clinical trial using pain as the primary endpoint for OGX-011, the timing and costs of clinical trials and regulatory approvals, risks that clinical trials will not be successful or confirm earlier or interim clinical trial results, the Company's need for additional financing, the uncertainty associated with any potential partnering discussions, risks relating to the development, safety and efficacy of therapeutic drugs and potential applications for these products and the risk factors set forth in the Company's filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K for fiscal year 2008. No assurances can be given that any of the events anticipated by the forward-looking statements will transpire or occur, or that if any of them do transpire or occur, what impact they would have on the results of operations or financial condition of the Company. The Company undertakes no obligation to update the forward-looking statements contained herein or to reflect events or circumstances occurring after the date hereof.

               Condensed Consolidated Statements of Operations
                               (in thousands)

                                    Three Months Ended        Year Ended
                                       December 31,          December 31,
                                       2008       2007       2008       2007
                                       (unaudited)
    Operating expenses
      Research and development     $  4,198   $  1,060   $  7,819   $  4,135
      General and administrative      1,050        831      3,293      3,540
                                   --------------------  --------------------
    Total oper
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12

Related biology technology :

1. OncoGenex reports lead drug candidate OGX-011 achieved primary endpoint in Phase 2 Trial with second-line chemotherapy for prostate cancer
2. Sonus Pharmaceuticals and OncoGenex Technologies to Merge
3. OncoGenex to present at the Needham & Company 7th Annual Biotechnology & Medical Technology Conference
4. OncoGenex increases economic interest in lead cancer drug OGX-011
5. OncoGenex receives completed Special Protocol Assessment for primary registration study of lead drug candidate OGX-011
6. Sonus Pharmaceuticals and OncoGenex Technologies complete business combination; OncoGenex Pharmaceuticals to commence trading on NASDAQ Capital Market today
7. FDA Grants Fast Track Designation for OncoGenex Pharmaceuticals Lead Product Candidate OGX-011
8. OncoGenex Pharmaceuticals announces out-license of TOCOSOL Paclitaxel to Eagle Pharmaceuticals
9. OncoGenex To Present At The BioContact Quebec 2008 Annual Conference
10. OncoGenex Achieves Key Regulatory Milestone for Lead Product Candidate, OGX-011
11. OncoGenex Pharmaceuticals to Release Third Quarter Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/31/2014)... , the leading life sciences employment and news website, launched the ... Illinois , Indiana , ... , Minnesota , Missouri , ... Wisconsin . BioMidwest is a leader in biotech and ... in this region in 2013. The life sciences sector in this area ...
(Date:7/31/2014)... a good reason people over 60 are not donor ... and weakens with time, making the elderly prone to ... Francisco research team now has discovered a reason why. ... the inability of blood-forming cells to maintain blood production ... molecular defects that could be restored for rejuvenation therapies," ...
(Date:7/31/2014)... see through organs and even the entire body to ... cellular structures has been a long-time dream of biologists. ... 31st in the journal Cell has now ... making opaque organs, bodies, and human tissue biopsies transparent, ... protocols could pave the way for a better understanding ...
(Date:7/31/2014)... BLOOMINGTON, Ind. -- Chemists at Indiana University Bloomington ... in bricks-and-mortar fashion, a development with potential value ... as field-effect transistors and photovoltaic cells. , Their ... 3D Crystalline Solids and 2D Self-Assembled Crystals," has ... a journal of the Royal Society of Chemistry. ...
Breaking Biology Technology:Midwest Biotech Leaders Featured On BioSpace Map 2Key to aging immune system is discovered 2See-through organs and bodies will accelerate biomedical discoveries 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 2Chemists demonstrate 'bricks-and-mortar' assembly of new molecular structures 3
... 16 The Endocrine Society, an,international association focused on ... analysts. The call,originated from ENDO 08, the annual conference ... Francisco. The Society has over 14,000 members from 80,countries, ... the latest,advances in endocrine research and clinical care., ...
... Anesiva,Inc. (Nasdaq: ANSV ) today announced the appointment ... a member of the company,s board of,directors, effective June ... as chief executive officer and member of the Anesiva ... to the,company., "Michael is the ideal person to ...
... today announced,the appointment of Rudy Mazzocchi as its ... responsible for leveraging the company,s novel,technology to find ... with,impaired vision have access to NovaVision(R) Vision Restoration ... bringing new medical technologies,and devices to market that ...
Cached Biology Technology:'Breakthroughs Ahead,' Endocrine Society Tells Security Analysts 2Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors 2Anesiva Names Michael L. Kranda as President, Chief Executive Officer and Member of Its Board of Directors 3NovaVision Appoints Medical Technology Veteran Rudy Mazzocchi as Chief Executive Officer 2NovaVision Appoints Medical Technology Veteran Rudy Mazzocchi as Chief Executive Officer 3
(Date:7/31/2014)... GAINESVILLE, Fla. --- By tracing nearly 3,000 genes ... moths, University of Florida scientists have created an ... to use large-scale, next-generation DNA sequencing. , ... more closely related to small moths than to ... how butterflies evolved. The study also found that ...
(Date:7/31/2014)... NCT00518336) shows the sustained efficacy, immunogenicity and ... vaccine Cervarix. Women vaccinated with the HPV-16/18 ... nine years, and vaccine efficacy (VE) against ... longest follow-up report for a licensed HPV ... full paper. , HPV and vaccination ...
(Date:7/31/2014)... This news release is available in German . ... (MOFs) can take up gases similar to a sponge ... are suited for storing hydrogen or greenhouse gases. However, ... of Karlsruhe Institute of Technology (KIT) now report in ... by cor-rosion of the MOF surface. This can be ...
Breaking Biology News(10 mins):UF study advances 'DNA revolution,' tells butterflies' evolutionary history 2UF study advances 'DNA revolution,' tells butterflies' evolutionary history 3Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 2Sustained efficacy, immunogenicity, and safety for GlaxoSmithKline's HPV vaccine 3Free pores for molecule transport 2
... 2012 Scientists from the Florida campus of The Scripps ... the National Institute on Drug Abuse of the National Institutes ... relapse in smokers who are kicking the habit. The ... is designed to support an institutionally based research program with ...
... fish species can decline while others may grow, reveals new ... in fish. The gastrointestinal system in fish is much ... even be a limiting factor for the distribution of species, ... looking at how gut function in various fish species is ...
... Conn., May 14, 2012 /PRNewswire-iReach/ -- Global ... reports on RNA interference (RNAi) and its relationship with ... Global Industry Analysts, new RNA Interference ... forecasts for drug discovery and target validation, reagents, and ...
Cached Biology News:Scripps Florida scientists awarded $8.4 million grant to develop new anti-smoking treatments 2The gut could reveal effect of climate change on fish 2Understanding the RNAi Reagents Market Overlap with Drug Discovery and Therapeutic Development is Critical for Pharmaceutical Leaders 2
... This CLS number is ... to easily match Cornings product ... yet, please order under the ... contact customer service for assistance. ...
... Invasion Assay is designed to determine the ... a significant barrier to invasion or to ... a convenient, high-throughput, 96-well format. The 8 ... types of adherent cells such as epithelial, ...
... GrabIt™ Kits are designed for the study ... a pull-down method. Proteins that interact with ... fusion proteins are copurified using affinity resins ... retained on a spin filter. The complexes ...
Kit containing MACS equipment and reagents for immunopurification of proteins....
Biology Products: